Microcap Akers Biosciences Spikes on Covid-Vaccine Progress

Akers Biosciences  (AKER) – Get Report shares jumped after the microcap biopharmaceutical company said its partner had completed a Covid-19 vaccine prototype. 

Premas Biotech, Akers’s partner, says it’s one of the first labs to obtain microscopic images of the Covid virus-like particles assembled in yeast. 

VLPs are the key to developing vaccines to combat coronavirus. The particles resemble native virions immunologically, while they are also non-replicating and non-pathogenic. 

“We are encouraged by the recent progress made with Premas,” Akers Executive Chairman Christopher Schreiber said in a statement. 

Source link

Leave a Reply

%d bloggers like this: